Literature DB >> 28820849

Correspondence.

Andrzej Grzybowski1, Stephen G Schwartz, Nidhi Relhan, Harry W Flynn.   

Abstract

Entities:  

Year:  2017        PMID： 28820849      PMCID： PMC5667553          DOI： 10.1097/IAE.0000000000001807

Source DB:  PubMed          Journal:  Retina        ISSN： 0275-004X            Impact factor:   4.256


× No keyword cloud information.
  9 in total

1.  LOW ENDOPHTHALMITIS RATES AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS IN AN OPERATION ROOM: A Retrospective Multicenter Study.

Authors:  Florentina J Freiberg; Troels Brynskov; Marion R Munk; Torben L Sørensen; Sebastian Wolf; Magdalena A Wirth; Matthias Becker; Stephan Michels
Journal:  Retina       Date:  2017-12       Impact factor: 4.256

2.  Endophthalmitis After Intravitreal Injections: Incidence, Presentation, Management, and Visual Outcome.

Authors:  Denis Dossarps; Alain M Bron; Philippe Koehrer; Ludwig S Aho-Glélé; Catherine Creuzot-Garcher
Journal:  Am J Ophthalmol       Date:  2015-04-16       Impact factor: 5.258

3.  No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting.

Authors:  Troels Brynskov; Henrik Kemp; Torben L Sørensen
Journal:  Retina       Date:  2014-05       Impact factor: 4.256

4.  Current Infectious Endophthalmitis Rates After Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents and Outcomes of Treatment.

Authors:  Ninel Z Gregori; Harry W Flynn; Stephen G Schwartz; Philip J Rosenfeld; Kamyar Vaziri; Andrew A Moshfeghi; Jorge A Fortun; Jaclyn L Kovach; Sander R Dubovy; Thomas A Albini; Janet L Davis; Audina M Berrocal; William E Smiddy
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2015-06       Impact factor: 1.300

5.  Endophthalmitis associated with intravitreal injections: office-based setting and operating room setting.

Authors:  Homayoun Tabandeh; Francesco Boscia; Alessandra Sborgia; Lorenza Ciracì; Pouya Dayani; Cesare Mariotti; Claudio Furino; Harry W Flynn
Journal:  Retina       Date:  2014-01       Impact factor: 4.256

6.  Postinjection Endophthalmitis Rates and Characteristics Following Intravitreal Bevacizumab, Ranibizumab, and Aflibercept.

Authors:  Nadim Rayess; Ehsan Rahimy; Philip Storey; Chirag P Shah; Jeremy D Wolfe; Eric Chen; Francis Char DeCroos; Sunir J Garg; Jason Hsu
Journal:  Am J Ophthalmol       Date:  2016-03-02       Impact factor: 5.258

7.  Endophthalmitis after intravitreal injection: decreasing incidence and clinical outcome-8-year results from a tertiary ophthalmic referral center.

Authors:  Martin M Nentwich; Yazmin Yactayo-Miranda; Fabian Schwarzbach; Armin Wolf; Anselm Kampik; Herminia Mino de Kaspar
Journal:  Retina       Date:  2014-05       Impact factor: 4.256

8.  Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study.

Authors:  Heather Casparis; Thomas J Wolfensberger; Matthias Becker; Gerhard Eich; Nicole Graf; Aude Ambresin; Irmela Mantel; Stephan Michels
Journal:  Retina       Date:  2014-01       Impact factor: 4.256

Review 9.  Global reported endophthalmitis risk following intravitreal injections of anti-VEGF: a literature review and analysis.

Authors:  Douglas K Sigford; Shivani Reddy; Christine Mollineaux; Shlomit Schaal
Journal:  Clin Ophthalmol       Date:  2015-05-02
  9 in total
  1 in total

Review 1.  Endophthalmitis: Then and Now.

Authors:  Nidhi Relhan; Richard K Forster; Harry W Flynn
Journal:  Am J Ophthalmol       Date:  2017-12-05       Impact factor: 5.258
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.